BCM
APTO

Bayesian Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Bayesian Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-84
Closed -$51K – 961
2021
Q4 		$51K Buy
+84
New +$78.9K 0.02% 352

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's APTO Position: Q1 2022 in Review

Bayesian Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q1 2022, closing a stake of 84 shares — an estimated $51K sold.

Bayesian Capital Management first reported a position in APTO in Q4 2021 and held it in 1 quarter. The position peaked at $51K in Q4 2021. 52 funds tracked by Wall St. Rank hold APTO as of Q1 2022.

  • Bayesian Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 84 Aptose Biosciences, Inc. shares in Q1 2022, an estimated $51K.
  • Bayesian Capital Management first reported a position in Aptose Biosciences, Inc. in Q4 2021 and held it in 1 quarter.
  • Bayesian Capital Management's Aptose Biosciences, Inc. position peaked at $51K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2022.

Based on Bayesian Capital Management's 13F filing for Q1 2022, filed 16 May 2022.